However, the mutation driven WTX silencing is rare and diverse in hepatoblastoma and CRC patients10–13, it suggests that there might be some other mechanisms responsible for WTX gene silencing and loss in those patients. This evidence concerns the gene AMER1 and colorectal carcinoma.